The ubiquitin proteasome system contains a plethora of novel therapeutic targets. Progenra’s ability to discover novel structures employing its high throughput assays has created several opportunities for establishing partnerships with other companies.
Recognizing that: 1) there is still much to discover in the ubiquitin-proteasome system; and 2) there is a need for rigorous validation of ubiquitin proteasome system targets, Progenra encourages academic laboratories to contact us with potential collaborative projects. Progenra is especially interested in prospective collaborations with translational potential.
We are pleased to have collaborations with several leading national and international academic institutions, including:.
|Baylor College of Medicine||University of Alabama at Birmingham|
|Children’s Hospital of Philadelphia||University of California, San Diego|
|Chinese Academy of Sciences||University of Illinois Chicago|
|Harvard University Dana-Farber Cancer Institute||University of Toronto|
|Emory University||University of Michigan Medical Center|
|Curie Institute Paris||University of Oxford|
|Johns Hopkins University School of Medicine||University of Pennsylvania School of Medicine|
|Karolinska Institute||University of Pittsburgh|
|Massachusetts General Hospital||University of Texas M D Anderson Cancer Center|